Bristol-Myers Squibb Company
COMBINATION THERAPY WITH ANTI-IL-8 ANTIBODIES AND ANTI-PD-1 ANTIBODIES FOR TREATING CANCER
Last updated:
Abstract:
Provided herein are methods for the clinical treatment of tumors (e.g., advanced solid tumors) in patients having certain levels of serum IL-8 using an anti-IL-8 antibody in combination with an anti-PD-1 antibody.
Status:
Application
Type:
Utility
Filling date:
11 Jan 2019
Issue date:
25 Feb 2021